Edge Therapeutics (NASDAQ:EDGE) is scheduled to announce its earnings results on Wednesday, February 28th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.
Shares of Edge Therapeutics (NASDAQ EDGE) opened at $15.56 on Tuesday. The company has a quick ratio of 8.34, a current ratio of 8.34 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $485.11, a price-to-earnings ratio of -9.97 and a beta of 3.32. Edge Therapeutics has a twelve month low of $7.30 and a twelve month high of $16.20.
Several analysts have recently weighed in on EDGE shares. BidaskClub upgraded Edge Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, February 5th. Zacks Investment Research upgraded Edge Therapeutics from a “sell” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Monday, November 6th. Finally, Credit Suisse Group restated an “outperform” rating and issued a $17.00 price objective on shares of Edge Therapeutics in a report on Thursday, January 18th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Edge Therapeutics presently has an average rating of “Buy” and a consensus target price of $20.00.
An institutional investor recently raised its position in Edge Therapeutics stock. State Street Corp lifted its stake in shares of Edge Therapeutics Inc (NASDAQ:EDGE) by 16.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 277,352 shares of the biotechnology company’s stock after purchasing an additional 38,909 shares during the period. State Street Corp owned approximately 0.90% of Edge Therapeutics worth $2,847,000 at the end of the most recent quarter. Institutional investors own 49.21% of the company’s stock.
Edge Therapeutics Company Profile
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.